UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Clinical pharmacology and therapeutics, 2017-11, Vol.102 (5), p.765-776

2017

Volltextzugriff (PDF)

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

International journal of molecular sciences, 2022-09, Vol.23 (17), p.9866

2022

Volltextzugriff (PDF)

Concise Drug Review: Azacitidine and Decitabine

The oncologist (Dayton, Ohio), 2013-05, Vol.18 (5), p.619-624

2013

Volltextzugriff (PDF)

Upfront Genotyping of DPYD2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Journal of clinical oncology, 2016-01, Vol.34 (3), p.227

2016

Volltextzugriff (PDF)

An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis

International journal of antimicrobial agents, 2022-01, Vol.59 (1), p.106459-106459, Article 106459

2022

Volltextzugriff (PDF)

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

Journal of antimicrobial chemotherapy, 2012-11, Vol.67 (11), p.2576-2597

2012

Volltextzugriff (PDF)

Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-10, Vol.1247, p.124308, Article 124308

2024

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Clinical pharmacokinetics, 2010-08, Vol.49 (8), p.493-507

2010

Volltextzugriff (PDF)

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Cell, 2018-05, Vol.173 (6), p.1413-1425.e14

2018

Volltextzugriff (PDF)

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Clinical pharmacokinetics, 2014-04, Vol.53 (4), p.305-325

2014

Volltextzugriff (PDF)

Fixed Dosing of Monoclonal Antibodies in Oncology

The oncologist (Dayton, Ohio), 2017-10, Vol.22 (10), p.1212-1221

2017

Volltextzugriff (PDF)

Variability in bioavailability of small molecular tyrosine kinase inhibitors

Cancer treatment reviews, 2015-05, Vol.41 (5), p.412-422

2015

Volltextzugriff (PDF)

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids

Cancer cell, 2011-09, Vol.20 (3), p.370-383

2011

Volltextzugriff (PDF)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2

Neoplasia (New York, N.Y.), 2018-07, Vol.20 (7), p.710-720

2018

Volltextzugriff (PDF)

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

European journal of clinical pharmacology, 2019-09, Vol.75 (9), p.1309-1318

2019

Volltextzugriff (PDF)

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

Cancer chemotherapy and pharmacology, 2022-06, Vol.89 (6), p.785-793

2022

Volltextzugriff (PDF)

Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies

European journal of cancer (1990), 2014-08, Vol.50 (12), p.2020-2036

2014

Volltextzugriff (PDF)

Improving Safety of Fluoropyrimidine Chemotherapy by Individualizing Treatment Based on Dihydropyrimidine Dehydrogenase Activity – Ready for Clinical Practice?

Cancer treatment reviews, 2016-11, Vol.50, p.23-34

2016

Volltextzugriff (PDF)

Gait dynamics to optimize fall risk assessment in geriatric patients admitted to an outpatient diagnostic clinic

PloS one, 2017-06, Vol.12 (6), p.e0178615-e0178615

2017

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

Clinical pharmacokinetics, 2022-12, Vol.61 (12), p.1649-1675

2022

Volltextzugriff (PDF)

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Journal of clinical oncology, 2016-12, Vol.34 (36), p.4354-4361

2016

Volltextzugriff (PDF)

Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics

European journal of cancer (1990), 2014-08, Vol.50 (12), p.2010-2019

2014

Volltextzugriff (PDF)

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

Clinical infectious diseases, 2013-06, Vol.56 (11), p.1530-1538

2013

Volltextzugriff (PDF)

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid

Journal of pharmaceutical and biomedical analysis, 2019-02, Vol.164, p.128-134

2019

Volltextzugriff (PDF)

1 – 25 von 1.270

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.187)
Mit Volltextzugriff
(1.116)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(948)
Journals@Ovid
(604)
Ingenta
(599)
EZB Electronic Journals Library
(453)
Springer journals
(284)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(269)
Access via ScienceDirect (Elsevier)
(259)
IngentaConnect Journals
(237)
NUS Single-Journal Subscriptions
(230)
Wiley-Blackwell Journals
(197)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(179)
Wiley Online Library
(130)
Nexis Uni
(81)
SAGE Journals
(37)
Oxford journals
(30)
Taylor & Francis Journals
(29)
Oxford Journals 2020 Medicine
(28)
Taylor & Francis
(28)
Nature
(14)
JSTOR
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

Concise Drug Review: Azacitidine and Decitabine

Upfront Genotyping of DPYD2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Fixed Dosing of Monoclonal Antibodies in Oncology

Variability in bioavailability of small molecular tyrosine kinase inhibitors

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies

Improving Safety of Fluoropyrimidine Chemotherapy by Individualizing Treatment Based on Dihydropyrimidine Dehydrogenase Activity – Ready for Clinical Practice?

Gait dynamics to optimize fall risk assessment in geriatric patients admitted to an outpatient diagnostic clinic

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid

Suchergebnisse filtern